Arylamine N-acetyltransferases which acetylate and inactivate isoniazid, an anti-tubercular drug, are found in mycobacteria including Mycobacterium smegmatis and Mycobacterium tuberculosis. We have solved the structure of arylamine N-acetyltransferase from M. smegmatis at a resolution of 1.7 A as a model for the highly homologous NAT from M. tuberculosis. The fold closely resembles that of NAT from Salmonella typhimurium, with a common catalytic triad and domain structure that is similar to certain cysteine proteases. The detailed geometry of the catalytic triad is typical of enzymes which use primary alcohols or thiols as activated nucleophiles. Thermal mobility and structural variations identify parts of NAT which might undergo conformati...
Arylamine N-acetyltransferases (NATs) catalyze the transfer of an acetyl group from acetyl-CoA to ar...
Arylamine N-acetyltransferase (NAT) was first identified in humans for its role in metabolising the ...
New anti-tubercular drugs and drug targets are urgently needed to reduce the time for treatment and ...
Arylamine N-acetyltransferase (NAT) acetylates the front-line anti-tuberculosis drug isoniazid (INH)...
Polymorphic Human arylamine N-acetyltransferase (NAT2) inactivates the anti-tubercular drug isoniazi...
The arylamine iV-acetyltransferases (NATs) catalyse the transfer of an acetyl group from the co-fact...
The arylamine N-acetyltransferases (NATs) are a unique family of enzymes that catalyse the transfer ...
Abstract: Polymorphic Human arylamine N-acetyltransferase (NAT2) inactivates the anti-tubercular dru...
Arylamine N-acetyltransferases (NATs, E.C. 2.1.3.5) are enzymes which are found in both eukaryotic a...
Treatment of latent tuberculosis infection remains an important goal of global TB eradication. To th...
Arylamine N-acetyltansferase (NAT) from Mycobacterium tuberculosis (TBNAT) is a potential drug targe...
International audienceMycobacterium abscessus is the most pathogenic rapid-growing mycobacterium and...
Arylamine N-acetyltransferases (NATs) are a family of phase II drug-metabolising enzymes which are i...
Arylamine N-acetyltransferase (NAT) was first identified as the inactivator of the anti-tubercular d...
AbstractThe arylamine N-acetyltransferases (NAT; EC 2.3.1.5) are xenobiotic-metabolizing enzymes (XM...
Arylamine N-acetyltransferases (NATs) catalyze the transfer of an acetyl group from acetyl-CoA to ar...
Arylamine N-acetyltransferase (NAT) was first identified in humans for its role in metabolising the ...
New anti-tubercular drugs and drug targets are urgently needed to reduce the time for treatment and ...
Arylamine N-acetyltransferase (NAT) acetylates the front-line anti-tuberculosis drug isoniazid (INH)...
Polymorphic Human arylamine N-acetyltransferase (NAT2) inactivates the anti-tubercular drug isoniazi...
The arylamine iV-acetyltransferases (NATs) catalyse the transfer of an acetyl group from the co-fact...
The arylamine N-acetyltransferases (NATs) are a unique family of enzymes that catalyse the transfer ...
Abstract: Polymorphic Human arylamine N-acetyltransferase (NAT2) inactivates the anti-tubercular dru...
Arylamine N-acetyltransferases (NATs, E.C. 2.1.3.5) are enzymes which are found in both eukaryotic a...
Treatment of latent tuberculosis infection remains an important goal of global TB eradication. To th...
Arylamine N-acetyltansferase (NAT) from Mycobacterium tuberculosis (TBNAT) is a potential drug targe...
International audienceMycobacterium abscessus is the most pathogenic rapid-growing mycobacterium and...
Arylamine N-acetyltransferases (NATs) are a family of phase II drug-metabolising enzymes which are i...
Arylamine N-acetyltransferase (NAT) was first identified as the inactivator of the anti-tubercular d...
AbstractThe arylamine N-acetyltransferases (NAT; EC 2.3.1.5) are xenobiotic-metabolizing enzymes (XM...
Arylamine N-acetyltransferases (NATs) catalyze the transfer of an acetyl group from acetyl-CoA to ar...
Arylamine N-acetyltransferase (NAT) was first identified in humans for its role in metabolising the ...
New anti-tubercular drugs and drug targets are urgently needed to reduce the time for treatment and ...